Table 4. Uptake of tamoxifen in various clinical situations.

Type of clinical situation	Uptake (%)	Reference
Non-trial, non-BRCA1/2
Surgical practice—4 surgeons	2/47 (4.7)	Port et al, 2001
Post-biopsy. Referred to general practice	1/89 (1.1)	Taylor and Taguchi, 2005
Referred to surgical service	57/137 (42.0)	Tchou et al, 2004
High-risk clinic	37/158 (29.0)	Bober et al, 2004
High-risk clinic	15/48 (31.0)	Layeequr Rahman and Crawford, 2009
High-risk clinic	136/1279 (10.6)	Donnelly et al—this study
Health-care systems	3/652 (0.5)	Fagerlin et al, 2010
Population (US) 2000	27/10 601(0.25)	Waters et al, 2010
2005	8/10 690 (0.08)	Waters et al, 2010
2010	32/9 906 (0.32)	Waters et al, 2012
Non-trial, BRCA1/2
International study	76/1135 (5.5)	Metcalfe et al, 2008
Multicentre study (Canada)	17/270 (6.0)	Metcalfe et al, 2007
High-risk clinic	7/170 (4.1)	Donnelly et al—this study
Trial recruitment
IBIS-I	32/278 (11.5)	Evans et al, 2001
IBIS-I	273/2278 (12.0)	Evans et al, 2010
STAR	35/158 (27.0)	Bober et al, 2004
STAR	19 747/91 325 (21.6)	McCaskill-Stevens et al, 2013
P1	13 954/57 641 (24.2)	Fisher et al, 2005

Abbreviations: IBIS-I=International Breast Cancer Intervention Study I; STAR= Study of Tamoxifen and Raloxifene.